Safety of systemic anti-cancer treatment in oncology patients with non-severe COVID-19: a cohort study

BACKGROUND: The viral pandemic coronavirus disease 2019 (COVID-19) has disrupted cancer patient management around the world. Most reported data relate to incidence, risk factors, and outcome of severe COVID-19. The safety of systemic anti-cancer therapy in oncology patients with non-severe COVID-19...

Descripción completa

Detalles Bibliográficos
Autores principales: van Marcke, C., Honoré, N., van der Elst, A., Beyaert, S., Derouane, F., Dumont, C., Aboubakar Nana, F., Baurain, J. F., Borbath, I., Collard, P., Cornélis, F., De Cuyper, A., Duhoux, F. P., Filleul, B., Galot, R., Gizzi, M., Mazzeo, F., Pieters, T., Seront, E., Sinapi, I., Van den Eynde, M., Whenham, N., Yombi, J. C., Scohy, A., van Maanen, A., Machiels, J. P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8134961/
https://www.ncbi.nlm.nih.gov/pubmed/34016086
http://dx.doi.org/10.1186/s12885-021-08349-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8134961/
https://www.ncbi.nlm.nih.gov/pubmed/34016086
http://dx.doi.org/10.1186/s12885-021-08349-8

Ejemplares similares